<DOC>
	<DOCNO>NCT01812330</DOCNO>
	<brief_summary>The purpose study compare efficacy safety ticagrelor clopidogrel</brief_summary>
	<brief_title>Efficacy Safety Study Ticagrelor</brief_title>
	<detailed_description>180 elective percutaneous coronary intervention patient clopidogrel resistance randomize three group , Group 1 : receive clopidogrel 75mg qd ; Group 2 : receive clopidogrel 150mg qd ; Group 3 : receive ticagrelor 90mg bid PCI.Platelet funtion test flowcytometric vasodilator-stimulated phosphoprotein ( VASP ) analysis PCI , 3days,7days 1 month PCI , respectively.The aim study compare efficacy safety ticagrelor clopidogrel</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1.Clinical diagnosis ACS 2.undergoing PCI 3.with clopidogrel resistance 1.any contraindication use clopidogrel ticagrel 2.Contradiction aspirin contrast medium 3.Life expectancy less 1 year 4.Tumor inflammatory diseases5 . fibrinolytic therapy within 24 hour randomization 6.a need oral anticoagulation therapy 7. increase risk bradycardia 8.concomitant therapy strong cytochrome P450 3A inhibitor inducer 9.a history asthma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>ACS</keyword>
	<keyword>CR</keyword>
	<keyword>PCI</keyword>
	<keyword>Platelet funtion</keyword>
	<keyword>Ticagrelor</keyword>
</DOC>